Study of Autologous Platelet Rich Plasma Injection to Improve Ovarian Function in Women with Poor Ovarian Response

What this Trial Is About

This trial focuses on women experiencing poor ovarian response POR, a challenging condition often linked to advanced maternal age that results in fewer eggs retrieved during fertility treatments and higher cycle cancellation rates. The study aims to evaluate whether autologous platelet rich plasma PRP infusion into the ovaries can improve ovarian response and hormone levels in women undergoing intracytoplasmic sperm injection ICSI. This is an interventional, non-randomized open-label study involving a large and well-controlled POR patient group. Participants in the experimental group receive autologous PRP intraovarian infusion during the mid-luteal phase, followed by a stimulated fresh embryo transfer-ICSI cycle in the first month after infusion. PRP is prepared from approximately 60 mL of the participants blood and injected into both ovaries under ultrasound guidance with minimal sedation. A control group undergoes the standard stimulated fresh embryo transfer-ICSI cycle without PRP treatment. The study compares these two approaches to assess PRPs effect on ovarian function. During the study, participants will be monitored for the number of oocytes retrieved after ovulation triggering and anti-Mullerian hormone AMH levels early in the menstrual cycle post-intervention. Additional assessments include clinical pregnancy rates and antral follicle count AFC. The study involves blood collection, ultrasound monitoring, and hormone testing to evaluate ovarian function and treatment impact. The trial extends until 2028, with comprehensive follow-up to measure key fertility outcomes.

Autologous Platelet Rich Plasma Intraovarian Infusion for Poor Responders